Lancet Infect Dis by Osorio, Jorge E et al.
Supplementary webappendix
This webappendix formed part of the original submission and has been peer reviewed. 
We post it as supplied by the authors. 
Supplement to: Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a 
recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive 
healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. 
Lancet Infect Dis 2014; published online July 24. http://dx.doi.org/10.1016/S1473-
3099(14)70811-4.






























After first dose           
Solicited systemic adverse 
events 
16 (84%) 4 (80%) 16 (76%) 1 (33%) 16 (76%) 2 (50%) 16 (89%) 4 (80%) 64 (81%) 11 (65%) 
Fever 1 (5%) 1 (20%) 2 (10%) 0 1 (5%) 0 1 (6%) 0 5 (6%) 1 (6%) 
Headache 11 (60%) 2 (40%) 11 (52%) 1 (33%) 9 (43%) 1 (25%) 8 (44%) 2 (40%) 39 (49%) 6 (35%) 
Muscle pain 8 (42%) 0 2 (10%) 1 (33%) 5 (24%) 0 6 (33%) 0 21 (27%) 1 (6%) 
Joint pain 5 (26%) 0 1 (5%) 0 2 (10%) 0 3 (17%) 0 11 (14%) 0 
Eye pain 7 (37%) 1 (20%) 8 (38%) 0 3 (14%) 1 (25%) 2 (11%) 2 (40%) 20 (25%) 4 (24%) 
Photophobia 3 (16%) 0 2 (10%) 0 2 (10%) 1 (25%) 3 (17%) 2 (40%) 10 (13%) 3 (18%) 
Fatigue 10 (53%) 1 (20%) 6 (29%) 0 5 (24%) 0 10 (56%) 4 (80%) 31 (39%) 5 (29%) 
Body rash 0 0 1 (5%) 0 2 (10%) 0 4 (22%) 0 7 (9%) 0 
Nausea 5 (26%) 2 (40%) 5 (24%) 0 5 (24%) 0 4 (22%) 2 (40%) 19 (24%) 4 (24%) 
Vomiting 0 0 0 0 1 (5%) 0 1 (6%) 0 2 (3%) 0 
Other 6 (37%) 1 (20%) 5 (24%) 0 11 (52%) 2 (50%) 5 (28%) 2 (40%) 27 (34%) 5 (29%) 
After second dose           
Solicited systemic adverse 
events 
10 (53%) 2 (40%) 15 (71%) 1 (33%) 10 (48%) 1 (25%) 13 (72%) 2 (40%) 48 (61%) 6 (35%) 
Fever 2 (11%) 0 1 (5%) 1 (33%) 0 1 (25%) 1 (6%) 0 4 (5%) 2 (12%) 
Headache 5 (27%) 1 (20%) 11 (52%) 1 (33%) 5 (24%) 0 9 (50%) 1 (20%) 30 (38%) 3 (18%) 
Muscle pain 3 (16%) 0 3 (14%) 1 (33%) 2 (10%) 0 2 (11%) 0 10 (13%) 1 (6%) 
Joint pain 1 (5%) 0 2 (10%) 0 2 (10%) 0 0 0 5 (6%) 0 
Eye pain 3 (16%) 1 (20%) 5 (24%) 1 (33%) 1 (5%) 0 7 (39%) 1 (20%) 16 (20%) 3 (17%) 
Photophobia 2 (11%) 1 (20%) 5 (24%) 1 (33%) 3 (14%) 0 2 (11%) 0 12 (15%) 2 (12%) 
Fatigue 7 (37%) 1 (20%) 7 (33%) 1 (33%) 4 (19%) 0 10 (56%) 1 (20%) 28 (35%) 3 (18%) 
Body rash 0 0 0 1 (33%) 0 0 0 0 0 1 (6%) 
Nausea 2 (11) 0 2 (10) 1 (33) 1 (5) 0 5 (28) 0 10 (13) 1 (6) 
Vomiting 1 (5) 0 0 0 1 (5) 0 2 (11) 0 4 (5) 0 
Other 3 (16) 0 3 (14) 0 5 (24) 0 1 (6) 1 (20) 12 (15) 1 (6) 
 
Data are n (%), unless otherwise indicated.  
Table 1: Number of patients with solicited systemic adverse events after the first or the second dose  






























After first dose           
Solicited local adverse 
events 
13 (68%) 1 (20%) 17 (81%) 1 (33%) 14 (66%) 1 (25%) 18 (100%) 1 (20%) 62 (79%) 4 (24%) 
Pain 12 (63%) 1 (20%) 6 (27%) 1 (33%) 4 (19%) 0 11 (61%) 1 (20%) 33 (42%) 3 (18%) 
Redness 6 (32%) 0 17 (81%) 0 11 (52%) 1 (25%) 16 (89%) 0 50 (63%) 1 (6%) 
Swelling 5 (26%) 0 6 (29%) 0 6 (29%) 0 6 (33%) 0 23 (29%) 0 
Itching 3 (16%) 0 5 (24%) 0 7 (33%) 1 (25%) 8 (44%) 1 (20%) 23 (29%) 2 (12%) 
After second dose           
Solicited local adverse 
events 
11 (58%) 0 19 (91%) 2 (66%)  8 (38%) 0 15 (83%) 0 53 (67%) 2 (12%) 
Pain 8 (42%) 0 4 (19%) 2 (66%) 7 (33%) 0 5 (28%) 0 24 (30%) 2 (12%) 
Redness 2 (11%) 0 19 (91%) 0 6 (29%) 0 12 (67%) 0 39 (49%) 0 
Swelling 1 (5%) 0 12 (57%) 0 3 (14%) 0 6 (33%) 0 22 (28%) 0 
Itching 4 (21%) 0 10 (48%) 1 (33%) 2 (10%) 0 12 (67%) 0 28 (35%) 1 (6%) 
Data are n (%), unless otherwise indicated. Percentages are based on the number of patients in the safety population (including the five who withdrew who did not receive a second dose). 
Table 2: Number of patients with solicited local adverse events after the first or the second dose 
  
























































    





























































































































































































































































































































 Data are mean (SD). ALT=alanine transaminase. AST=aspartate transaminase. 
Table 3: Clinical laboratory findings after DENVax administration  
 
        
